Introduction {#sec1_1}
============

Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor required for the proliferation and differentiation of hematopoietic precursors of neutrophil granulocytes \[[@B1]\].

G-CSF-producing bladder tumor is still a rare entity, and only 75 cases have been reported in Japan, all showing a poor prognosis \[[@B2], [@B3], [@B4], [@B5]\]. Due to the rarity of this disease, there are no established treatments.

We herein report a rare case of G-CSF-producing bladder tumor.

Case Presentation {#sec1_2}
=================

A 67-year-old woman was referred to our hospital for the further examination of gross hematuria. Cystoscopy revealed a 7-cm bladder tumor in her left bladder wall (Fig. [1](#F1){ref-type="fig"}). Urinary cytology showed class IIIb. She had a history of schizophrenia for 45 years. Laboratory data showed almost normal findings, except for an elevated white blood cell (WBC) count (17,100/μL; Neutro 79.8%, Baso 1.1%, Eos 1.1%, Mono 6.8%, Lymph 11.2%). CT and MRI revealed a 2.2-cm left iliac lymph node metastasis and suspected colon invasion (Fig. [2](#F2){ref-type="fig"}).

Two months after her initial visit, transurethral resection of bladder tumor (TUR-Bt) was performed. The tumor occupied from the left side wall to the anterior wall, with a 7- to 8-cm diameter. A pathological examination revealed highly invasive urothelial carcinoma with squamous cell differentiation (Grade 3, High Grade) with partial expression of G-CSF (Fig. [3](#F3){ref-type="fig"}). Due to her schizophrenia and lymph node metastasis, she and her family sought no further treatment. She ultimately died of bladder cancer 6 months after her initial visit (Fig. [4](#F4){ref-type="fig"}).

Discussion {#sec1_3}
==========

Colony-stimulating factors promote WBC differentiation and proliferation through stem cells in the bone marrow \[[@B6]\]. G-CSF is one such colony-stimulating factor produced by macrophages and fibroblasts.

G-CSF-producing tumors secrete cytokines and increase the WBC count. The lung is the most frequent site of G-CSF-producing tumor formation, followed by the stomach, thyroid, and liver. G-CSF-producing tumors are diagnosed by the following four criteria: an elevated WBC count in the peripheral blood, an elevated serum G-CSF level, G-CSF expression in the tumor tissue, and a reduction in the WBC count or G-CSF expression in the serum following tumor resection or treatment \[[@B6]\]. Recent technology has facilitated the confirmation of the expression of G-CSF using an enzyme immunoassay (EIA) to detect serum G-CSF levels \[[@B3]\]. The present case showed an elevated WBC count, and immunohistochemistry detected G-CSF expression in the tumor tissue.

Previous reports have shown that the WBC count and serum G-CSF level were correlated with G-CSF-producing cancer progression, so these two factors have been considered tumor markers. Most reported G-CSF-producing tumors have shown a poor outcome. G-CSF-producing tumors tend to display G-CSF receptors, so autocrine tumor progression and resulting in introducing tumor progression.

A low pre-therapeutic serum G-CSF level and control of the WBC count after tumor resection are thought to be favorable outcome factors \[[@B7]\]. The present case showed a fever and elevated serum CRP level. While some previously reported cases have shown systemic inflammation, G-CSF itself does not induce a fever or CRP elevation. The mechanism underlying the appearance of a fever and CRP elevation is thought to involve the production of systemic cytokines, including IL-1 and IL-6, by this aggressive tumor. Some inflammation was also observed \[[@B4]\].
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![(**a**) HE staining and (**b**) immunohistochemistry of G-CSF of the tumor. (**a**) High grade urothelial carcinoma cells were seen in the left, and keratinizing squamous components in the right. (**b**) Immunohistochemically, G-CSF was focally observed in the tumor cells.](cro-0012-0603-g03){#F3}
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